Rifampin combination therapy for nonmycobacterial infections

Clinical Microbiology Reviews

Volumn 23, Issue 1, 2010, Pages 14-34

  Forrest, Graeme N ^a,b   Tamura, Kimberly ^a  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; BOSENTAN; CLOFIBRATE; CONTRACEPTIVE AGENT; CORTICOSTEROID; CYCLOSPORIN; DIGOXIN; DILTIAZEM; DISOPYRAMIDE; ESTROGEN; GLIBENCLAMIDE; LORCAINIDE; METOPROLOL; MEXILETINE; MYCOPHENOLIC ACID; NIFEDIPINE; PIOGLITAZONE; PROPAFENONE; RANOLAZINE; RAPAMYCIN; REPAGLINIDE; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT; ROSIGLITAZONE; SIMVASTATIN; TACROLIMUS; TAMOXIFEN; THYROXINE; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIAL GENE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BLOOD PLACENTA BARRIER; BODY FLUID; BREAST MILK; CEREBROSPINAL FLUID; CYTOPENIA; DEVICE INFECTION; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG FEVER; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; ENDOCARDITIS; ENZYME INDUCTION; ESOPHAGITIS; GENE DELETION; GENE INSERTION; GENE MUTATION; GRAM NEGATIVE BACTERIUM; HALF LIFE TIME; HEPATITIS C; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY FAILURE; LEGIONELLA; LIVER FAILURE; LIVER TOXICITY; LUNG ASPERGILLOSIS; MENINGITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUTROPENIA; OSTEOMYELITIS; PNEUMONIA; POINT MUTATION; REVIEW; RHODOCOCCUS; SHUNT INFECTION; SIDE EFFECT; STAPHYLOCOCCUS; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; DRUG THERAPY, COMBINATION; HUMANS; PROSTHESIS-RELATED INFECTIONS; RIFAMPIN; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME;

EID: 74249103796     PISSN: 08938512     EISSN: 10986618     Source Type: Journal    
DOI: 10.1128/CMR.00034-09     Document Type: Review

References (282)

1. Aboltins, C. A., M. A. Page, K. L. Buising, A. W. Jenney, J. R. Daffy, P. F. Choong, and P. A. Stanley. 2007. Treatment of staphylococcal prosthetic joint infections with debridement, prosthesis retention and oral rifampicin and fusidic acid. Clin. Microbiol. Infect. 13:586-591.
2. Acosta, E. P., M. A. Kendall, J. G. Gerber, B. Alston-Smith, S. L. Koletar, A. R. Zolopa, S. Agarwala, M. Child, R. Bertz, L. Hosey, and D. W. Haas. 2007. Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. Antimicrob. Agents Chemother. 51:3104-3110.
3. Aepinus, C., E. Adolph, C. von Eiff, A. Podbielski, and M. Petzsch. 2008. Kytococcus schroeteri: a probably underdiagnosed pathogen involved in prosthetic valve endocarditis. Wien. Klin. Wochenschr. 120:46-49. (In German.)
4. Ampel, N. M., and E. J. Wing. 1990. Legionella infection in transplant patients. Semin. Respir. Infect. 5:30-37.
5. Antony, S. J. 2006. Combination therapy with daptomycin, vancomycin, and rifampin for recurrent, severe bone and prosthetic joint infections involving methicillin-resistant Staphylococcus aureus. Scand. J. Infect. Dis. 38:293-295.
6. Araujo, F. G., A. A. Khan, and J. S. Remington. 1996. Rifapentine is active in vitro and in vivo against Toxoplasma gondii. Antimicrob. Agents Chemother. 40:1335-1337.
7. Archer, G. L., B. C. Armstrong, and B. J. Kline. 1982. Rifampin blood and tissue levels in patients undergoing cardiac valve surgery. Antimicrob. Agents Chemother. 21:800-803.
8. Archer, G. L., M. J. Tenenbaum, and H. B. Haywood III. 1978. Rifampin therapy of Staphylococcus epidermidis. Use in infections from indwelling artificial devices. JAMA 240:751-753.
9. Arnold, T. M., G. N. Forrest, and K. J. Messmer. 2007. Polymyxin antibiotics for gram-negative infections. Am. J. Health Syst. Pharm. 64:819-826.
10. Asakura, T., K. Aoki, M. Tadokoro, H. Tanaka, and S. Furuta. 1996. A case report of active aortic prosthetic valve endocarditis due to methicillinresistant Staphylococcus epidermidis. Nippon Kyobu Geka Gakkai Zasshi 44:1185-1192. (In Japanese.)
11. Asoh, N., H. Watanabe, M. Fines-Guyon, K. Watanabe, K. Oishi, W. Kositsakulchai, T. Sanchai, K. Kunsuikmengrai, S. Kahintapong, B. Khantawa, P. Tharavichitkul, T. Sirisanthana, and T. Nagatake. 2003. Emergence of rifampin-resistant Rhodococcus equi with several types of mutations in the rpoB gene among AIDS patients in northern Thailand. J. Clin. Microbiol. 41:2337-2340.
12. Aspinall, S. L., D. M. Friedland, V. L. Yu, J. D. Rihs, and R. R. Muder. 1995. Recurrent methicillin-resistant Staphylococcus aureus osteomyelitis: combination antibiotic therapy with evaluation by serum bactericidal titers. Ann. Pharmacother. 29:694-697.
13. Atlas, E., and M. Turck. 1968. Laboratory and clinical evaluation of rifampicin. Am. J. Med. Sci. 256:47-54.
14. Baciewicz, A. M., C. R. Chrisman, C. K. Finch, and T. H. Self. 2008. Update on rifampin and rifabutin drug interactions. Am. J. Med. Sci. 335:126-136.
15. Baddour, L. M., W. R. Wilson, A. S. Bayer, V. G. Fowler, Jr., A. F. Bolger, M. E. Levison, P. Ferrieri, M. A. Gerber, L. Y. Tani, M. H. Gewitz, D. C. Tong, J. M. Steckelberg, R. S. Baltimore, S. T. Shulman, J. C. Burns, D. A. Falace, J. W. Newburger, T. J. Pallasch, M. Takahashi, and K. A. Taubert. 2005. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 111:e394-e434.
16. Baldoni, D., M. Haschke, Z. Rajacic, W. Zimmerli, and A. Trampuz. 2009. Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection. Antimicrob. Agents Chemother. 53:1142-1148.
17. Bals, M. G., and S. Filipescu. 1969. The antistaphylococcal activity of rifampicin. Arzneimittelforschung 19:1285-1287.
18. Baltch, A. L., R. P. Smith, and W. Ritz. 1995. Inhibitory and bactericidal activities of levofloxacin, ofloxacin, erythromycin, and rifampin used singly and in combination against Legionella pneumophila. Antimicrob. Agents Chemother. 39:1661-1666.
19. Bamberger, D. M., M. T. Fields, and B. L. Herndon. 1991. Efficacies of various antimicrobial agents in treatment of Staphylococcus aureus abscesses and correlation with in vitro tests of antimicrobial activity and neutrophil killing. Antimicrob. Agents Chemother. 35:2335-2339.
20. Barberán, J., L. Aguilar, G. Carroquino, M. J. Giménez, B. Sanchez, D. Martinez, and J. Prieto. 2006. Conservative treatment of staphylococcal prosthetic joint infections in elderly patients. Am. J. Med. 119:993.e7-993.e10.
21. Barberán, J., L. Aguilar, M. J. Giménez, G. Carroquino, J. J. Granizo, and J. Prieto. 2008. Levofloxacin plus rifampicin conservative treatment of 25 early staphylococcal infections of osteosynthetic devices for rigid internal fixation. Int. J. Antimicrob. Agents 32:154-157.
22. Bassetti, M., E. Repetto, E. Righi, S. Boni, M. Diverio, M. P. Molinari, M. Mussap, S. Artioli, F. Ansaldi, P. Durando, G. Orengo, P. F. Bobbio, and C. Viscoli. 2008. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J. Antimicrob. Chemother. 61:417-420.
23. Bastin, R., J. C. Pechere, C. Tancrede, D. Sicard, and J. P. Harpey. 1968. Initial results of treament with rifampicin of some septicemic states, 4 of which with endocarditis. Bull. Mem. Soc. Med. Hop. Paris 119:527-534. (In French.)
24. Baty, V., B. Hoen, H. Schuhmacher, C. Amiel, M. Reyrolle, H. Garin, and P. Canton. 1997. Legionella jordanis pneumonia unresponsive to fluoroquinolones in a non-immunocompromised host. Scand. J. Infect. Dis. 29:319-320.
25. Bayer, A. S., and K. Lam. 1985. Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: in vitro-in vivo correlations. J. Infect. Dis. 151:157-165.
26. Bayer, A. S., and J. O. Morrison. 1984. Disparity between timed-kill and checkerboard methods for determination of in vitro bactericidal interactions of vancomycin plus rifampin versus methicillin-susceptible and -resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 26:220-223.
27. Beggs, W. H., G. A. Sarosi, and M. I. Walker. 1976. Synergistic action of amphotericin B and rifampin against Candida species. J. Infect. Dis. 133:206-209.
28. Bennett, J. W., C. K. Murray, R. L. Holmes, J. E. Patterson, and J. H. Jorgensen. 2008. Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus. Diagn. Microbiol. Infect. Dis. 60:437-440.
29. Berdal, J. E., I. Skråmm, P. Mowinckel, P. Gulbrandsen, and J. V. Bjørnholt. 2005. Use of rifampicin and ciprofloxacin combination therapy after surgical debridement in the treatment of early manifestation prosthetic joint infections. Clin. Microbiol. Infect. 11:843-845.
30. Binda, G., E. Domenichini, A. Gottardi, B. Orlandi, E. Ortelli, B. Pacini, and G. Fowst. 1971. Rifampicin, a general review. Arzneimittelforschung 21:1907-1977.
31. Blount, J. P., J. A. Campbell, and S. J. Haines. 1993. Complications in ventricular cerebrospinal fluid shunting. Neurosurg. Clin. N. Am. 4:633-656.
32. Bolton, A. E., B. Peng, M. Hubert, A. Krebs-Brown, R. Capdeville, U. Keller, and M. Seiberling. 2004. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother. Pharmacol. 53:102-106.
33. Borin, M. T., J. H. Chambers, B. J. Carel, S. Gagnon, and W. W. Freimuth. 1997. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. Clin. Pharmacol. Ther. 61:544-553.
34. Boucher, H. W., G. H. Talbot, J. S. Bradley, J. E. Edwards, D. Gilbert, L. B. Rice, M. Scheld, B. Spellberg, and J. Bartlett. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1-12.
35. Boulle, A., G. Van Cutsem, K. Cohen, K. Hilderbrand, S. Mathee, M. Abrahams, E. Goemaere, D. Coetzee, and G. Maartens. 2008. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 300:530-539.
36. Brandt, C. M., M. S. Rouse, B. M. Tallan, N. W. Laue, W. R. Wilson, and J. M. Steckelberg. 1995. Effective treatment of cephalosporin-rifampin combinations against cryptic methicillin-resistant beta-lactamase-producing coagulase-negative staphylococcal experimental endocarditis. Antimicrob. Agents Chemother. 39:1815-1819.
37. Brandt, C. M., M. S. Rouse, B. M. Tallan, W. R. Wilson, and J. M. Steckelberg. 1994. Failure of time-kill synergy studies using subinhibitory antimicrobial concentrations to predict in vivo antagonism of cephalosporin-rifampin combinations against Staphylococcus aureus. Antimicrob. Agents Chemother. 38:2191-2193.
38. Brandt, C. M., W. W. Sistrunk, M. C. Duffy, A. D. Hanssen, J. M. Steckelberg, D. M. Ilstrup, and D. R. Osmon. 1997. Staphylococcus aureus prosthetic joint infection treated with debridement and prosthesis retention. Clin. Infect. Dis. 24:914-919.
39. Brennan-Benson, P., R. Lyus, T. Harrison, M. Pakianathan, and D. Macallan. 2005. Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all. AIDS 19:1541-1543.
40. Cabrera, S. E., M. Cordero, A. Iglesias, M. P. Valverde, A. Domínguez-Gil, and M. J. García. 2008. Efavirenz-rifampicin interaction: therapeutic drug monitoring to efavirenz dosage optimization in HIV/TBC patients. AIDS 22:2549-2551.
41. Campbell, E. A., N. Korzheva, A. Mustaev, K. Murakami, S. Nair, A. Goldfarb, and S. A. Darst. 2001. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 104:901-912.
42. Carter, M. 2004. IDV concentrations plummet with rifampicin. IAPAC Mon. 10:53.
43. Chambers, H. F., X. Q. Liu, L. L. Chow, and C. Hackbarth. 1999. Efficacy of levofloxacin for experimental aortic-valve endocarditis in rabbits infected with viridans group streptococcus or Staphylococcus aureus. Antimicrob. Agents Chemother. 43:2742-2746.
44. Chamovitz, B., R. E. Bryant, D. N. Gilbert, and A. I. Hartstein. 1985. Prosthetic valve endocarditis caused by Staphylococcus epidermidis. Development of rifampin resistance during vancomycin and rifampin therapy. JAMA 253:2867-2868.
45. Chandrasekaran, S., and D. Lalithakumari. 1998. Plasmid-mediated rifampicin resistance in Pseudomonas fluorescens. J. Med. Microbiol. 47:197-200.
46. Chenhsu, R. Y., C. C. Loong, M. H. Chou, M. F. Lin, and W. C. Yang. 2000. Renal allograft dysfunction associated with rifampin-tacrolimus interaction. Ann. Pharmacother. 34:27-31.
47. Choong, P. F., M. M. Dowsey, D. Carr, J. Daffy, and P. Stanley. 2007. Risk factors associated with acute hip prosthetic joint infections and outcome of treatment with a rifampin based regimen. Acta Orthop. 78:755-765.
48. Chow, J. W., M. Hilf, and V. L. Yu. 1991. Synergistic interaction of antibiotics with nasal penetration to methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 27:558-560.
49. Chow, J. W., and V. L. Yu. 1998. Legionella: a major opportunistic pathogen in transplant recipients. Semin. Respir. Infect. 13:132-139.
50. Christenson, J. C., I. Shalit, D. F. Welch, A. Guruswamy, and M. I. Marks. 1987. Synergistic action of amphotericin B and rifampin against Rhizopus species. Antimicrob. Agents Chemother. 31:1775-1778.
51. Chuard, C., M. Herrmann, P. Vaudaux, F. A. Waldvogel, and D. P. Lew. 1991. Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations. Antimicrob. Agents Chemother. 35:2611-2616.
52. Cocohoba, J., and B. J. Dong. 2008. Raltegravir: the first HIV integrase inhibitor. Clin. Ther. 30:1747-1765.
53. Colebunders, R., J. P. Ursi, S. Pattyn, and J. Snoeck. 1985. Prosthetic valve endocarditis due to methicillin-resistant Staphylococcus epidermidis and Micrococcus species successfully treated with rifampicin combined with other antibiotics. J. Infect. 11:35-39.
54. Colmenero, J. D., L. C. Fernández-Gallardo, J. A. Agúndez, J. Sedeño, J. Benítez, and E. Valverde. 1994. Possible implications of doxycyclinerifampin interaction for treatment of brucellosis. Antimicrob. Agents Chemother. 38:2798-2802.
55. Conen, A., L. N. Walti, A. Merlo, U. Fluckiger, M. Battegay, and A. Trampuz. 2008. Characteristics and treatment outcome of cerebrospinal fluid shunt-associated infections in adults: a retrospective analysis over an 11-year period. Clin. Infect. Dis. 47:73-82.
56. Cormican, M. G., M. E. Erwin, and R. N. Jones. 1995. Bactericidal activity of cefotaxime, desacetylcefotaxime, rifampin, and various combinations tested at cerebrospinal fluid levels against penicillin-resistant Streptococcus pneumoniae. Diagn. Microbiol. Infect. Dis. 22:119-123.
57. Cosgrove, S. E., and V. G. Fowler, Jr. 2008. Management of methicillinresistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 46(Suppl. 5):S386-S393.
58. Costerton, J. W., P. S. Stewart, and E. P. Greenberg. 1999. Bacterial biofilms: a common cause of persistent infections. Science 284:1318-1322.
59. Credito, K., G. Lin, and P. C. Appelbaum. 2007. Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology. Antimicrob. Agents Chemother. 51:1504-1507.
60. Cronin, S. M., M. H. Abidi, C. J. Shearer, P. H. Chandrasekar, and R. B. Ibrahim. 2008. Rhodococcus equi lung infection in an allogeneic hematopoietic stem cell transplant recipient. Transpl. Infect. Dis. 10:48-51.
61. Cruciani, M., G. Gatti, L. Lazzarini, G. Furlan, G. Broccali, M. Malena, C. Franchini, and E. Concia. 1996. Penetration of vancomycin into human lung tissue. J. Antimicrob. Chemother. 38:865-869.
62. Dailey, C. F., P. J. Pagano, L. V. Buchanan, J. A. Paquette, J. V. Haas, and J. K. Gibson. 2003. Efficacy of linezolid plus rifampin in an experimental model of methicillin-susceptible Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 47:2655-2658.
63. Darouiche, R. O., A. Dhir, A. J. Miller, G. C. Landon, I. I. Raad, and D. M. Musher. 1994. Vancomycin penetration into biofilm covering infected prostheses and effect on bacteria. J. Infect. Dis. 170:720-723.
64. Darouiche, R. O., and R. J. Hamill. 1994. Antibiotic penetration of and bactericidal activity within endothelial cells. Antimicrob. Agents Chemother. 38:1059-1064.
65. Daver, N. G., S. A. Shelburne, R. L. Atmar, T. P. Giordano, C. E. Stager, C. A. Reitman, and A. C. White, Jr. 2007. Oral step-down therapy is comparable to intravenous therapy for Staphylococcus aureus osteomyelitis. J. Infect. 54:539-544.
66. Desplaces, N., and J. F. Acar. 1988. New quinolones in the treatment of joint and bone infections. Rev. Infect. Dis. 10(Suppl. 1):S179-S183.
67. Djojosaputro, M., S. S. Mustofa, S. Suryawati, and B. Santoso. 1990. The effects of doses and pre-treatment with rifampicin on the elimination kinetics of metronidazole. Eur. J. Pharmacol. 138:1870-1871.
68. Doble, N., R. Shaw, C. Rowland-Hill, M. Lush, D. W. Warnock, and E. E. Keal. 1988. Pharmacokinetic study of the interaction between rifampicin and ketoconazole. J. Antimicrob. Chemother. 21:633-635.
69. Donaldson, A. D., R. C. Chan, and I. B. Gosbell. 2006. Community-acquired methicillin-resistant Staphylococcus aureus in bone and joint infections: development of rifampicin resistance. Med. J. Aust. 184:196.
70. Donlan, R. M. 2000. Role of biofilms in antimicrobial resistance. ASAIO J. 46:S47-S52.
71. Drayton, J., G. Dickinson, and M. G. Rinaldi. 1994. Coadministration of rifampin and itraconazole leads to undetectable levels of serum itraconazole. Clin. Infect. Dis. 18:266.
72. Dubois, J., and C. St.-Pierre. 1999. In vitro activity of gatifloxacin, compared with ciprofloxacin, clarithromycin, erythromycin, and rifampin, against Legionella species. Diagn. Microbiol. Infect. Dis. 33:261-265.
73. Dworkin, R., G. Modin, S. Kunz, R. Rich, O. Zak, and M. Sande. 1990. Comparative efficacies of ciprofloxacin, pefloxacin, and vancomycin in combination with rifampin in a rat model of methicillin-resistant Staphylococcus aureus chronic osteomyelitis. Antimicrob. Agents Chemother. 34:1014-1016.
74. Dworkin, R. J., B. L. Lee, M. A. Sande, and H. F. Chambers. 1989. Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin. Lancet ii:1071-1073.
75. Edwards, J. E., Jr., J. Morrison, D. K. Henderson, and J. Z. Montgomerie. 1980. Combined effect of amphotericin B and rifampin on Candida species. Antimicrob. Agents Chemother. 17:484-487.
76. Egle, H., R. Trittler, K. Kummerer, and S. W. Lemmen. 2005. Linezolid and rifampin: drug interaction contrary to expectations? Clin. Pharmacol. Ther. 77:451-453.
77. Ellington, J. K., M. Harris, M. C. Hudson, S. Vishin, L. X. Webb, and R. Sherertz. 2006. Intracellular Staphylococcus aureus and antibiotic resistance: implications for treatment of staphylococcal osteomyelitis. J. Orthop. Res. 24:87-93.
78. Eng, R. H., S. M. Smith, F. J. Buccini, and C. E. Cherubin. 1985. Differences in ability of cell-wall antibiotics to suppress emergence of rifampicin resistance in Staphylococcus aureus. J. Antimicrob. Chemother. 15:201-207.
79. Falagas, M. E., K. Fragoulis, I. A. Bliziotis, and I. Chatzinikolaou. 2007. Rifampicin-impregnated central venous catheters: a meta-analysis of randomized controlled trials. J. Antimicrob. Chemother. 59:359-369.
80. Falcone, M., F. Campanile, M. Giannella, S. Borbone, S. Stefani, and M. Venditti. 2007. Staphylococcus haemolyticus endocarditis: clinical and microbiologic analysis of 4 cases. Diagn. Microbiol. Infect. Dis. 57:325-331.
81. Fang, G. D., J. E. Stout, V. L. Yu, A. Goetz, J. D. Rihs, and R. M. Vickers. 1990. Community-acquired pneumonia caused by Legionella dumoffii in a patient with hairy cell leukemia. Infection 18:383-385.
82. Farber, B. F., Y. C. Yee, and A. W. Karchmer. 1986. Interaction between rifampin and fusidic acid against methicillin-resistant coagulase-positive and -negative staphylococci. Antimicrob. Agents Chemother. 30:174-175.
83. Fass, R. J., and V. L. Helsel. 1987. In vitro antistaphylococcal activity of pefloxacin alone and in combination with other antistaphylococcal drugs. Antimicrob. Agents Chemother. 31:1457-1460.
84. Ferrándiz, M. J., C. Ardanuy, J. Liñares, J. M. Garcia-Arenzana, E. Cercenado, A. Fleites, and A. G. de la Campa. 2005. New mutations and horizontal transfer of rpoB among rifampin-resistant Streptococcus pneumoniae from four Spanish hospitals. Antimicrob. Agents Chemother. 49:2237-2245.
85. Finch, C. K., C. R. Chrisman, A. M. Baciewicz, and T. H. Self. 2002. Rifampin and rifabutin drug interactions: an update. Arch. Intern. Med. 162:985-992.
86. Foldes, M., R. Munro, T. C. Sorrell, S. Shanker, and M. Toohey. 1983. In-vitro effects of vancomycin, rifampicin, and fusidic acid, alone and in combination, against methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 11:21-26.
87. Foo, S. S., and D. C. Lye. 2007. Methicillin-sensitive Staphylococcus aureus tricuspid valve endocarditis with annular abscess cured with oral levofloxacin and rifampicin. Int. J. Antimicrob. Agents 30:275-277.
88. Force, E., F. Taberner, C. Cabellos, S. Ribes, A. Domenech, F. Tubau, P. F. Viladrich, and F. Gudiol. 2009. Evaluation of meropenem alone and combined with rifampin in the guinea pig model of pneumococcal meningitis. Eur. J. Clin. Microbiol. Infect. Dis. 28:807-811.
89. Fowler, C. E., J. S. Soothill, and L. Oakes. 1997. MICs of rifampicin and chloramphenicol for mucoid Pseudomonas aeruginosa strains are lower when human lactoferrin is present. J. Antimicrob. Chemother. 40:877-879.
90. Fowler, V. G., Jr., H. W. Boucher, G. R. Corey, E. Abrutyn, A. W. Karchmer, M. E. Rupp, D. P. Levine, H. F. Chambers, F. P. Tally, G. A. Vigliani, C. H. Cabell, A. S. Link, I. DeMeyer, S. G. Filler, M. Zervos, P. Cook, J. Parsonnet, J. M. Bernstein, C. S. Price, G. N. Forrest, G. Fatkenheuer, M. Gareca, S. J. Rehm, H. R. Brodt, A. Tice, and S. E. Cosgrove. 2006. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 355:653-665.
91. Frame, P. T., and R. L. McLaurin. 1984. Treatment of CSF shunt infections with intrashunt plus oral antibiotic therapy. J. Neurosurg. 60:354-360.
92. Fridkin, S. K., J. C. Hageman, M. Morrison, L. T. Sanza, K. Como-Sabetti, J. A. Jernigan, K. Harriman, L. H. Harrison, R. Lynfield, and M. M. Farley. 2005. Methicillin-resistant Staphylococcus aureus disease in three communities. N. Engl. J. Med. 352:1436-1444.
93. Friedland, I. R., and G. H. McCracken, Jr. 1994. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N. Engl. J. Med. 331:377-382.
94. Friedland, I. R., M. Paris, S. Shelton, and G. H. McCracken. 1994. Timekill studies of antibiotic combinations against penicillin-resistant and -susceptible Streptococcus pneumoniae. J. Antimicrob. Chemother. 34:231-237.
95. Fujita, N. K., and J. E. Edwards, Jr. 1981. Combined in vitro effect of amphotericin B and rifampin on Cryptococcus neoformans. Antimicrob. Agents Chemother. 19:196-198.
96. Gagnon, R. F., G. K. Richards, and G. B. Kostiner. 1994. Time-kill efficacy of antibiotics in combination with rifampin against Staphylococcus epidermidis biofilms. Adv. Perit. Dial. 10:189-192.
97. Gallicano, K. D., J. Sahai, V. K. Shukla, I. Seguin, A. Pakuts, D. Kwok, B. C. Foster, and D. W. Cameron. 1999. Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients. Br. J. Clin. Pharmacol. 48:168-179.
98. Gebhart, B. C., B. C. Barker, and B. A. Markewitz. 2007. Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin. Pharmacotherapy 27:476-479.
99. Geist, M. J., G. Egerer, J. Burhenne, K. D. Riedel, and G. Mikus. 2007. Induction of voriconazole metabolism by rifampin in a patient with acute myeloid leukemia: importance of interdisciplinary communication to prevent treatment errors with complex medications. Antimicrob. Agents Chemother. 51:3455-3456.
100. George, T., K. Burch, and D. J. Magilligan, Jr. 1980. Rifampin in the management of early prosthetic Staphylococcus epidermidis endocarditis. Ann. Thorac. Surg. 29:74-75.
101. Ghanem, K. G. 2005. Equivalence between oral and intravenous antibiotics when treating serious staphylococcal infections? Clin. Infect. Dis. 40:772-773.
102. Giamarellos-Bourboulis, E. J., E. Xirouchaki, and H. Giamarellou. 2001. Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii. Diagn. Microbiol. Infect. Dis. 40:117-120.
103. Gianella, S., S. Ulrich, B. Huttner, and R. Speich. 2006. Conservative management of a brain abscess in a patient with Staphylococcus lugdunensis endocarditis. Eur. J. Clin. Microbiol. Infect. Dis. 25:476-478.
104. GlaxoSmithKline. 2008. Mepron (atovaquone) suspension prescribing information. GlaxoSmithKline, Research Triangle Park, NC.
105. Gombert, M. E., S. H. Landesman, M. L. Corrado, S. C. Stein, E. T. Melvin, and M. Cummings. 1981. Vancomycin and rifampin therapy for Staphylococcus epidermidis meningitis associated with CSF shunts: report of three cases. J. Neurosurg. 55:633-636.
106. Gómez-Lus, R., F. Adrián, R. del Campo, P. Gómez-Lus, S. Sánchez, C. García, and M. C. Rubio. 2001. Comparative in vitro bacteriostatic and bactericidal activity of trovafloxacin, levofloxacin and moxifloxacin against clinical and environmental isolates of Legionella spp. Int. J. Antimicrob. Agents 18:49-54.
107. Gordon, R. C., R. Wofford-McQueen, and K. Shu. 1990. In vitro synergism of rifampin-cephalosporin combinations against Haemophilus influenzae type b. Eur. J. Clin. Microbiol. Infect. Dis. 9:201-205.
108. Grau, S., J. M. Antonio, E. Ribes, M. Salvado, J. M. Garces, and J. Garau. 2006. Impact of rifampicin addition to clarithromycin in Legionella pneumophila pneumonia. Int. J. Antimicrob. Agents 28:249-252.
109. Graziani, A. L., L. A. Lawson, G. A. Gibson, M. A. Steinberg, and R. R. MacGregor. 1988. Vancomycin concentrations in infected and noninfected human bone. Antimicrob. Agents Chemother. 32:1320-1322.
110. Grohs, P., M. D. Kitzis, and L. Gutmann. 2003. In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus. Antimicrob. Agents Chemother. 47:418-420.
111. Haas, D. W., S. L. Koletar, L. Laughlin, M. A. Kendall, C. Suckow, J. G. Gerber, A. R. Zolopa, R. Bertz, M. J. Child, L. Hosey, B. Alston-Smith, and E. P. Acosta. 2009. Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir. J. Acquir. Immune Defic. Syndr. 50:290-293.
112. Hackbarth, C. J., H. F. Chambers, and M. A. Sande. 1986. Serum bactericidal activity of rifampin in combination with other antimicrobial agents against Staphylococcus aureus. Antimicrob. Agents Chemother. 29:611-613.
113. Harvey, R. J. 1978. Antagonistic interaction of rifampicin and trimethoprim. J. Antimicrob. Chemother. 4:315-327.
114. Havlichek, D., D. Pohlod, and L. Saravolatz. 1987. Comparison of ciprofloxacin and rifampicin in experimental Legionella pneumophila pneumonia. J. Antimicrob. Chemother. 20:875-881.
115. Heldman, A. W., T. V. Hartert, S. C. Ray, E. G. Daoud, T. E. Kowalski, V. J. Pompili, S. D. Sisson, W. C. Tidmore, K. A. vom Eigen, S. N. Goodman, P. S. Lietman, B. G. Petty, and C. Flexner. 1996. Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. Am. J. Med. 101:68-76.
116. Heller, E., M. Argaman, H. Levy, and N. Goldblum. 1969. Selective inhibition of vaccinia virus by the antibiotic rifampicin. Nature 222:273-274.
117. Henry, N. K., M. S. Rouse, A. L. Whitesell, M. E. McConnell, and W. R. Wilson. 1987. Treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis with ciprofloxacin or vancomycin alone or in combination with rifampin. Am. J. Med. 82:73-75.
118. Hermsen, E. D., L. B. Hovde, J. R. Hotchkiss, and J. C. Rotschafer. 2003. Increased killing of staphylococci and streptococci by daptomycin compared with cefazolin and vancomycin in an in vitro peritoneal dialysate model. Antimicrob. Agents Chemother. 47:3764-3767.
119. Hessen, M. T., P. G. Pitsakis, and D. Kaye. 1990. Oral temafloxacin versus vancomycin for therapy of experimental endocarditis caused by methicillinresistant Staphylococcus aureus. Antimicrob. Agents Chemother. 34:1143-1145.
120. Hidayat, L. K., D. I. Hsu, R. Quist, K. A. Shriner, and A. Wong-Beringer. 2006. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch. Intern. Med. 166:2138-2144.
121. Ho, J. L., and M. S. Klempner. 1986. In vitro evaluation of clindamycin in combination with oxacillin, rifampin, or vancomycin against Staphylococcus aureus. Diagn. Microbiol. Infect. Dis. 4:133-138.
122. Holdiness, M. R. 1987. Rifampin drug interactions. Arch. Intern. Med. 147:1856.
123. Holston, A. M., and J. R. Miller. 2006. Primary lung abscess caused by multidrug-nonsusceptible Streptococcus pneumoniae in a child. Pediatr. Infect. Dis. J. 25:182-183.
124. Howden, B. P., P. B. Ward, P. G. Charles, T. M. Korman, A. Fuller, P. du Cros, E. A. Grabsch, S. A. Roberts, J. Robson, K. Read, N. Bak, J. Hurley, P. D. Johnson, A. J. Morris, B. C. Mayall, and M. L. Grayson. 2004. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin. Infect. Dis. 38:521-528.
125. Huengsberg, M., S. Castelino, J. Sherrard, N. O'Farrell, and J. Bingham. 1993. Does drug interaction cause failure of PCP prophylaxis with dapsone? Lancet 341:48.
126. Huppert, M., D. Pappagianis, S. H. Sun, I. Gleason-Jordan, M. S. Collins, and K. R. Vukovich. 1976. Effect of amphotericin B and rifampin against Coccidioides immitis in vitro and in vivo. Antimicrob. Agents Chemother. 9:406-413.
127. Jacobus Pharmaceutical Co. 2008. Dapsone oral tablet package insert. Jacobus Pharmaceutical Co., Princeton, NJ.
128. Jacqueline, C., J. Caillon, V. Le Mabecque, A. F. Miegeville, P. Y. Donnio, D. Bugnon, and G. Potel. 2003. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods. J. Antimicrob. Chemother. 51:857-864.
129. Jang, H. C., S. H. Kim, K. H. Kim, C. J. Kim, S. Lee, K. H. Song, J. H. Jeon, W. B. Park, H. B. Kim, S. W. Park, N. J. Kim, E. C. Kim, M. D. Oh, and K. W. Choe. 2009. Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem. Clin. Infect. Dis. 49:395-401.
130. Jensen, K. 1967. Combination therapy with antibacterial chemotherapeutic agents in staphylococcal infections. Ugeskr. Laeger 129:1019-1030. (In Danish.)
131. Jensen, K. 1968. Methicillin-resistant staphylococci. Lancet ii:1078.
132. John, A. K., D. Baldoni, M. Haschke, K. Rentsch, P. Schaerli, W. Zimmerli, and A. Trampuz. 2009. Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin. Antimicrob. Agents Chemother. 53:2719-2724.
133. John, M. D., P. L. Hibberd, A. W. Karchmer, L. A. Sleeper, and S. B. Calderwood. 1998. Staphylococcus aureus prosthetic valve endocarditis: optimal management and risk factors for death. Clin. Infect. Dis. 26:1302-1309.
134. Johnson, L. B., and L. D. Saravolatz. 2009. Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor. Clin. Infect. Dis. 48:1123-1128.
135. Johnston, B. L., R. Y. Kwok, and M. E. Mulligan. 1987. In vitro activity of novobiocin and rifampin alone and in combination against oxacillin-resistant Staphylococcus aureus. Diagn. Microbiol. Infect. Dis. 8:137-147.
136. Justesen, U. S., A. B. Andersen, N. A. Klitgaard, K. Brosen, J. Gerstoft, and C. Pedersen. 2004. Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients. Clin. Infect. Dis. 38:426-429.
137. Kaatz, G. W., S. M. Seo, S. L. Barriere, L. M. Albrecht, and M. J. Rybak. 1989. Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 33:1184-1187.
138. Kang, S. L., M. J. Rybak, B. J. McGrath, G. W. Kaatz, and S. M. Seo. 1994. Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model. Antimicrob. Agents Chemother. 38:2702-2709.
139. Karchmer, A. W. 1985. Staphylococcal endocarditis. Laboratory and clinical basis for antibiotic therapy. Am. J. Med. 78:116-127.
140. Karchmer, A. W., G. L. Archer, and W. E. Dismukes. 1983. Rifampin treatment of prosthetic valve endocarditis due to Staphylococcus epidermidis. Rev. Infect. Dis. 5(Suppl. 3):S543-S548.
141. Karchmer, A. W., G. L. Archer, and W. E. Dismukes. 1983. Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiologic and clinical observations as guides to therapy. Ann. Intern. Med. 98:447-455.
142. Kashuba, A. D. 2005. Drug-drug interactions and the pharmacotherapy of HIV infection. Top. HIV Med. 13:64-69.
143. Khasawneh, F. A., D. S. Ashcraft, and G. A. Pankey. 2008. In vitro testing of daptomycin plus rifampin against methicillin-resistant Staphylococcus aureus resistant to rifampin. Saudi Med. J. 29:1726-1729.
144. King, T. C., D. Schlessinger, and D. J. Krogstad. 1981. The assessment of antimicrobial combinations. Rev. Infect. Dis. 3:627-633.
145. Klevens, R. M., M. A. Morrison, J. Nadle, S. Petit, K. Gershman, S. Ray, L. H. Harrison, R. Lynfield, G. Dumyati, J. M. Townes, A. S. Craig, E. R. Zell, G. E. Fosheim, L. K. McDougal, R. B. Carey, and S. K. Fridkin. 2007. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298:1763-1771.
146. Klugman, K. P., I. R. Friedland, and J. S. Bradley. 1995. Bactericidal activity against cephalosporin-resistant Streptococcus pneumoniae in cerebrospinal fluid of children with acute bacterial meningitis. Antimicrob. Agents Chemother. 39:1988-1992.
147. Knox, K. L., and A. H. Holmes. 2002. Nosocomial endocarditis caused by Corynebacterium amycolatum and other nondiphtheriae corynebacteria. Emerg. Infect. Dis. 8:97-99.
148. Kobbayashi, G. S., G. Medoff, D. Schlessinger, C. N. Kwan, and W. E. Musser. 1972. Amphotericin B potentiation of rifampicin as an antifungal agent against the yeast phase of Histoplasma capsulatum. Science 177:709-710.
149. König, D. P., J. M. Schierholz, U. Münnich, and J. Rütt. 2001. Treatment of staphylococcal implant infection with rifampicin-ciprofloxacin in stable implants. Arch. Orthop. Trauma Surg. 121:297-299.
150. Kumar, A., R. Wofford-McQueen, and R. C. Gordon. 1989. Ciprofloxacin, imipenem and rifampicin: in-vitro synergy of two and three drug combinations against Pseudomonas cepacia. J. Antimicrob. Chemother. 23:831-835.
151. Kumar, B. D., C. E. Prasad, and K. Krishnaswamy. 1992. Detection of rifampicin-induced nephrotoxicity by N-acetyl-3-D-glucosaminidase activity.
152. Kunin, C. M., D. Brandt, and H. Wood. 1969. Bacteriologic studies of rifampin, a new semisynthetic antibiotic. J. Infect. Dis. 119:132-137.
153. Laffer, R. R., P. Graber, P. E. Ochsner, and W. Zimmerli. 2006. Outcome of prosthetic knee-associated infection: evaluation of 40 consecutive episodes at a single centre. Clin. Microbiol. Infect. 12:433-439.
154. Lazzarini, L., B. A. Lipsky, and J. T. Mader. 2005. Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials? Int. J. Infect. Dis. 9:127-138.
155. Levine, D. P., B. S. Fromm, and B. R. Reddy. 1991. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann. Intern. Med. 115:674-680.
156. Li, J., R. L. Nation, R. J. Owen, S. Wong, D. Spelman, and C. Franklin. 2007. Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains. Clin. Infect. Dis. 45:594-598.
157. López-Cortés, L. F., R. Ruiz-Valderas, P. Viciana, A. Alarcón-González, J. Gómez-Mateos, E. León-Jimenez, M. Sarasanacenta, Y. López-Pua, and J. Pachón. 2002. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin. Pharmacokinet. 41:681-690.
158. Lowy, F. D., D. S. Chang, and P. R. Lash. 1983. Synergy of combinations of vancomycin, gentamicin, and rifampin against methicillin-resistant, coagulase-negative staphylococci. Antimicrob. Agents Chemother. 23:932-934.
159. Lucet, J. C., M. Herrmann, P. Rohner, R. Auckenthaler, F. A. Waldvogel, and D. P. Lew. 1990. Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 34:2312-2317.
160. Maduri, T. M., D. A. Goldmann, and P. Murphy. 1983. In vitro activity of rifampin in combination with oxacillin against Staphylococcus aureus. Antimicrob. Agents Chemother. 23:571-576.
161. Mallolas, J., M. Sarasa, M. Nomdedeu, A. Soriano, Y. López-Púa, J. L. Blanco, E. Martínez, and J. M. Gatell. 2007. Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients. HIV Med. 8:131-134.
162. Mandell, G. L., and D. R. Moorman. 1980. Treatment of experimental staphylococcal infections: effect of rifampin alone and in combination on development of rifampin resistance. Antimicrob. Agents Chemother. 17:658-662.
163. Maor, Y., M. Hagin, N. Belausov, N. Keller, D. Ben-David, and G. Rahav. 2009. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J. Infect. Dis. 199:619-624.
164. Mascellino, M. T., E. Iona, R. Ponzo, C. M. Mastroianni, and S. Delia. 1994. Infections due to Rhodococcus equi in three HIV-infected patients: microbiological findings and antibiotic susceptibility. Int. J. Clin. Pharmacol. Res. 14:157-163.
165. McCabe, W. R., and V. Lorian. 1968. Comparison of the antibacterial activity of rifampicin and other antibiotics. Am. J. Med. Sci. 256:255-265.
166. McIlleron, H., G. Meintjes, W. J. Burman, and G. Maartens. 2007. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J. Infect. Dis. 196(Suppl. 1):S63-S75.
167. Meier, P. S., S. Utz, S. Aebi, and K. Muhlemann. 2003. Low-level resistance to rifampin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 47:863-868.
168. Mindermann, T., H. Landolt, W. Zimmerli, Z. Rajacic, and O. Gratzl. 1993. Penetration of rifampicin into the brain tissue and cerebral extracellular space of rats. J. Antimicrob. Chemother. 31:731-737.
169. Mnif, B., I. Boujelbene, F. Mahjoubi, R. Gdoura, I. Trabelsi, S. Moalla, I. Frikha, S. Kammoun, and A. Hammami. 2006. Endocarditis due to Kytococcus schroeteri: case report and review of the literature. J. Clin. Microbiol. 44:1187-1189.
170. Moellering, R. C., Jr. 1979. Antimicrobial synergism-an elusive concept. J. Infect. Dis. 140:639-641.
171. Moffie, B. G., and R. P. Mouton. 1988. Sensitivity and resistance of Legionella pneumophila to some antibiotics and combinations of antibiotics. J. Antimicrob. Chemother. 22:457-462.
172. Moneib, N. A. 1995. In-vitro activity of commonly used antifungal agents in the presence of rifampin, polymyxin B and norfloxacin against Candida albicans. J. Chemother. 7:525-529.
173. Moretti, F., E. Quiros-Roldan, S. Casari, P. Viale, A. Chiodera, and G. Carosi. 2002. Rhodococcus equi: pulmonary cavitation lesion in patient infected with HIV cured by levofloxacin and rifampicin. AIDS 16:1440-1442.
174. Morgan, J. R., K. W. Clarke, and S. G. Brear. 1993. Phenomenon of rifampicin-induced discolouration of body fluids. Respir. Med. 87:320-321.
175. Moss, B., E. N. Rosenblum, E. Katz, and P. M. Grimley. 1969. Rifampicin: a specific inhibitor of vaccinia virus assembly. Nature 224:1280-1284.
176. Motaouakkil, S., B. Charra, A. Hachimi, H. Nejmi, A. Benslama, N. Elmdaghri, H. Belabbes, and M. Benbachir. 2006. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J. Infect. 53:274-278.
177. Mulazimoglu, L., S. D. Drenning, and V. L. Yu. 1996. In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob. Agents Chemother. 40:2428-2430.
178. National Committee for Clinical Laboratory Standards. 1999. Methodology for the serum bactericidal test. Approved guidelines M21-a. National Committee for Clinical Laboratory Standards, Wayne, PA.
179. Nau, R., K. Kaye, M. Sachdeva, E. R. Sande, and M. G. Tauber. 1994. Rifampin for therapy of experimental pneumococcal meningitis in rabbits. Antimicrob. Agents Chemother. 38:1186-1189.
180. Nau, R., H. W. Prange, S. Menck, H. Kolenda, K. Visser, and J. K. Seydel. 1992. Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges. J. Antimicrob. Chemother. 29:719-724.
181. Nessi, R., and G. Fowst. 1979. Clinical use of rifampicin in combination for non-mycobacterial infections: a survey of published evidence. J. Int. Med. Res. 7:179-186.
182. Nicolau, D. P., H. M. Crowe, C. H. Nightingale, and R. Quintiliani. 1995. Rifampin-fluconazole interaction in critically ill patients. Ann. Pharmacother. 29:994-996.
183. Niemi, M., J. T. Backman, M. F. Fromm, P. J. Neuvonen, and K. T. Kivisto. 2003. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin. Pharmacokinet. 42:819-850.
184. Nijland, H. M., R. Ruslami, A. J. Suroto, D. M. Burger, B. Alisjahbana, R. van Crevel, and R. E. Aarnoutse. 2007. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin. Infect. Dis. 45:1001-1007.
185. Norden, C. W. 1983. Experimental chronic staphylococcal osteomyelitis in rabbits: treatment with rifampin alone and in combination with other antimicrobial agents. Rev. Infect. Dis. 5(Suppl. 3):S491-S494.
186. Norden, C. W., J. Fierer, and R. E. Bryant. 1983. Chronic staphylococcal osteomyelitis: treatment with regimens containing rifampin. Rev. Infect. Dis. 5(Suppl. 3):S495-S501.
187. Norden, C. W., and M. Shaffer. 1983. Treatment of experimental chronic osteomyelitis due to Staphylococcus aureus with vancomycin and rifampin. J. Infect. Dis. 147:352-357.
188. Nordmann, P., P. Chavanet, J. Caillon, J. M. Duez, and H. Portier. 1992. Recurrent pneumonia due to rifampicin-resistant Rhodococcus equi in a patient infected with HIV. J. Infect. 24:104-107.
189. Orvin, K., E. Bilavsky, E. Weiner, D. S. Shouval, and J. Amir. 2009. Successful antibiotic eradication of Streptococcus pneumoniae infection of a ventriculoatrial shunt. Int. J. Infect. Dis. 13:e101-e103.
190. Palmer, S. M., S. L. Kang, D. M. Cappelletty, and M. J. Rybak. 1995. Bactericidal killing activities of cefepime, ceftazidime, cefotaxime, and ceftriaxone against Staphylococcus aureus and beta-lactamase-producing strains of Enterobacter aerogenes and Klebsiella pneumoniae in an in vitro infection model. Antimicrob. Agents Chemother. 39:1764-1771.
191. Pankey, G., D. Ashcraft, and N. Patel. 2005. In vitro synergy of daptomycin plus rifampin against Enterococcus faecium resistant to both linezolid and vancomycin. Antimicrob. Agents Chemother. 49:5166-5168.
192. Panomvana Na, A. D., N. Thanompuangseree, and S. Tansuphaswadikul. 2004. Effect of rifampicin on the pharmacokinetics of fluconazole in patients with AIDS. Clin. Pharmacokinet. 43:725-732.
193. Paterson, D. L., and J. Lipman. 2007. Returning to the pre-antibiotic era in the critically ill: the XDR problem. Crit. Care Med. 35:1789-1791.
194. Peard, M. C., D. G. Fleck, L. P. Garrod, and P. M. Waterworth. 1970. Combined rifampicin and erythromycin for bacterial endocarditis. Br. Med. J. iv:410-411.
195. Peck, K. R., S. W. Kim, S. I. Jung, Y. S. Kim, W. S. Oh, J. Y. Lee, J. H. Jin, S. Kim, J. H. Song, and H. Kobayashi. 2003. Antimicrobials as potential adjunctive agents in the treatment of biofilm infection with Staphylococcus epidermidis. Chemotherapy 49:189-193.
196. Pedral-Sampaio, D. B., C. R. Alves, E. M. Netto, C. Brites, A. S. Oliveira, and R. Badaro. 2004. Efficacy and safety of efavirenz in HIV patients on rifampin for tuberculosis. Braz. J. Infect. Dis. 8:211-216.
197. Peloquin, C. A., R. Namdar, M. D. Singleton, and D. E. Nix. 1999. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest 115:12-18.
198. Perdikaris, G., H. Giamarellou, A. Pefanis, I. Donta, and P. Karayiannakos. 1995. Vancomycin or vancomycin plus netilmicin for methicillin- and gentamicin-resistant Staphylococcus aureus aortic valve experimental endocarditis. Antimicrob. Agents Chemother. 39:2289-2294.
199. Perlroth, J., M. Kuo, J. Tan, A. S. Bayer, and L. G. Miller. 2008. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch. Intern. Med. 168:805-819.
200. Petzsch, M., W. Leber, B. Westphal, S. Crusius, and E. C. Reisinger. 2004. Progressive Staphylococcus lugdunensis endocarditis despite antibiotic treatment. Wien. Klin. Wochenschr. 116:98-101. (In German.)
201. Phillips, I. 1971. Clinical uses and control of rifampicin and clindamycin. J. Clin. Pathol. 24:410-418.
202. Pien, F. D., and K. L. Vosti. 1974. Variation in performance of the serum bactericidal test. Antimicrob. Agents Chemother. 6:330-333.
203. Polk, R. E., D. F. Brophy, D. S. Israel, R. Patron, B. M. Sadler, G. E. Chittick, W. T. Symonds, Y. Lou, D. Kristoff, and D. S. Stein. 2001. Pharmacokinetic interaction between amprenavir and rifabutin or rifampin in healthy males. Antimicrob. Agents Chemother. 45:502-508.
204. Raad, I., R. Darouiche, J. Dupuis, D. Abi-Said, A. Gabrielli, R. Hachem, M. Wall, R. Harris, J. Jones, A. Buzaid, C. Robertson, S. Shenaq, P. Curling, T. Burke, and C. Ericsson. 1997. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. A randomized, double-blind trial. The Texas Medical Center Catheter Study Group. Ann. Intern. Med. 127:267-274.
205. Raad, I., and H. Hanna. 1999. Intravascular catheters impregnated with antimicrobial agents: a milestone in the prevention of bloodstream infections. Support. Care Cancer 7:386-390.
206. Raad, I., H. Hanna, Y. Jiang, T. Dvorak, R. Reitzel, G. Chaiban, R. Sherertz, and R. Hachem. 2007. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob. Agents Chemother. 51:1656-1660.
207. Ramachandran, G., A. K. Hemanthkumar, S. Rajasekaran, C. Padmapriyadarsini, G. Narendran, B. Sukumar, S. Sathishnarayan, K. Raja, V. Kumaraswami, and S. Swaminathan. 2006. Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration. J. Acquir. Immune Defic. Syndr. 42:36-41.
208. Rand, K. H., and H. Houck. 2004. Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci. J. Antimicrob. Chemother. 53:530-532.
209. Ren, Y., J. J. Nuttall, C. Egbers, B. S. Eley, T. M. Meyers, P. J. Smith, G. Maartens, and H. M. McIlleron. 2008. Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. J. Acquir. Immune Defic. Syndr. 47:566-569.
210. Ribera, E., C. Azuaje, R. M. Lopez, P. Domingo, A. Curran, M. Feijoo, L. Pou, P. Sánchez, M. A. Sambeat, J. Colomer, J. L. Lopez-Colomes, M. Crespo, V. Falcó, I. Ocaña, and A. Pahissa. 2007. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis. J. Antimicrob. Chemother. 59:690-697.
211. Ribes, S., F. Taberner, A. Domenech, C. Cabellos, F. Tubau, J. Liñares, V. P. Fernández, and F. Gudiol. 2005. Evaluation of ceftriaxone, vancomycin and rifampicin alone and combined in an experimental model of meningitis caused by highly cephalosporin-resistant Streptococcus pneumoniae ATCC 51916. J. Antimicrob. Chemother. 56:979-982.
212. Ribner, B., G. T. Keusch, B. A. Hanna, and M. Perloff. 1976. Combination amphotericin B-rifampin therapy for pulmonary aspergillosis in a leukemic patient. Chest 70:681-683.
213. Richards, J., J. Black, and C. Marshall. 2005. Methodological errors in staphylococcal equivalence study. Clin. Infect. Dis. 40:771-772.
214. Riedel, D. J., E. Weekes, and G. N. Forrest. 2008. Addition of rifampin to standard therapy for treatment of native valve Staphylococcus aureus infective endocarditis. Antimicrob. Agents Chemother. 52:2463-2467.
215. Saballs, M., M. Pujol, F. Tubau, C. Peña, A. Montero, M. A. Domínguez, F. Gudiol, and J. Ariza. 2006. Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections. J. Antimicrob. Chemother. 58:697-700.
216. Saginur, R., M. Stdenis, W. Ferris, S. D. Aaron, F. Chan, C. Lee, and K. Ramotar. 2006. Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections. Antimicrob. Agents Chemother. 50:55-61.
217. Sakoulas, G., G. M. Eliopoulos, J. Alder, and C. T. Eliopoulos. 2003. Efficacy of daptomycin in experimental endocarditis due to methicillinresistant Staphylococcus aureus. Antimicrob. Agents Chemother. 47:1714-1718.
218. Saleh-Mghir, A., N. Ameur, C. Muller-Serieys, F. Ismael, F. Lemaitre, L. Massias, C. Feger, R. Bléton, and A. C. Crémieux. 2002. Combination of quinupristin-dalfopristin (Synercid) and rifampin is highly synergistic in experimental Staphylococcus aureus joint prosthesis infection. Antimicrob. Agents Chemother. 46:1122-1124.
219. Sande, M. A., and M. L. Johnson. 1975. Antimicrobial therapy of experimental endocarditis caused by Staphylococcus aureus. J. Infect. Dis. 131:367-375.
220. Sanders, W. E., Jr. 1976. Rifampin. Ann. Intern. Med. 85:82-86.
221. Schering Corp. 2006. Noxafil (posaconazole) oral suspension (package insert). Schering Corp., Kenilworth, NJ.
222. Schrenzel, J., S. Harbarth, G. Schockmel, D. Genne, T. Bregenzer, U. Flueckiger, C. Petignat, F. Jacobs, P. Francioli, W. Zimmerli, and D. P. Lew. 2004. A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection. Clin. Infect. Dis. 39:1285-1292.
223. Schwalm, J. D., P. El-Helou, and C. H. Lee. 2004. Clinical outcome with oral linezolid and rifampin following recurrent methicillin-resistant Staphylococcus aureus bacteremia despite prolonged vancomycin treatment. Can. J. Infect. Dis. 15:97-100.
224. Segreti, J., L. C. Gvazdinskas, and G. M. Trenholme. 1989. In vitro activity of minocycline and rifampin against staphylococci. Diagn. Microbiol. Infect. Dis. 12:253-255.
225. Senneville, E., A. Lombart, E. Beltrand, M. Valette, L. Legout, M. Cazaubiel, Y. Yazdanpanah, and P. Fontaine. 2008. Outcome of diabetic foot osteomyelitis treated nonsurgically: a retrospective cohort study. Diabetes Care 31:637-642.
226. Senneville, E., Y. Yazdanpanah, M. Cazaubiel, M. Cordonnier, M. Valette, E. Beltrand, A. Khazarjian, L. Maulin, S. Alfandari, M. Caillaux, L. Dubreuil, and Y. Mouton. 2001. Rifampicin-ofloxacin oral regimen for the treatment of mild to moderate diabetic foot osteomyelitis. J. Antimicrob. Chemother. 48:927-930.
227. Simon, G. L., R. H. Smith, and M. A. Sande. 1983. Emergence of rifampinresistant strains of Staphylococcus aureus during combination therapy with vancomycin and rifampin: a report of two cases. Rev. Infect. Dis. 5(Suppl. 3):S507-S508.
228. Simsir, A., D. Oldach, G. Forest, and M. Henry. 2001. Rhodococcus equi and cytomegalovirus pneumonia in a renal transplant patient: diagnosis by fine-needle aspiration biopsy. Diagn. Cytopathol. 24:129-131.
229. Skhirtladze, K., D. Hutschala, T. Fleck, F. Thalhammer, M. Ehrlich, T. Vukovich, M. Muller, and E. M. Tschernko. 2006. Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery. Antimicrob. Agents Chemother. 50:1372-1375.
230. Smith, S. J., A. J. Lee, D. S. Maddix, and A. W. Chow. 1999. Pill-induced esophagitis caused by oral rifampin. Ann. Pharmacother. 33:27-31.
231. Souli, M., K. Pontikis, Z. Chryssouli, I. Galani, and H. Giamarellou. 2005. Successful treatment of right-sided prosthetic valve endocarditis due to methicillin-resistant teicoplanin-heteroresistant Staphylococcus aureus with linezolid. Eur. J. Clin. Microbiol. Infect. Dis. 24:760-762.
232. Stein, D. S., and C. R. Libertin. 1988. Time kill curve analysis of vancomycin and rifampin alone and in combination against nine strains of nutritionally deficient streptococci. Diagn. Microbiol. Infect. Dis. 10:139-144.
233. Stone, J. A., E. M. Migoya, L. Hickey, G. A. Winchell, P. J. Deutsch, K. Ghosh, A. Freeman, S. Bi, R. Desai, S. C. Dilzer, K. C. Lasseter, W. K. Kraft, H. Greenberg, and S. A. Waldman. 2004. Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob. Agents Chemother. 48:4306-4314.
234. Stratton, C. W. 1988. Serum bactericidal test. Clin. Microbiol. Rev. 1:19-26.
235. Subak-Sharpe, J. H., M. C. Timbury, and J. F. Williams. 1969. Rifampicin inhibits the growth of some mammalian viruses. Nature 222:341-345.
236. Suntur, B. M., T. Yurtseven, O. R. Sipahi, C. Buke, and M. Buke. 2005. Rifampicin+ceftriaxone versus vancomycin+ceftriaxone in the treatment of penicillin- and cephalosporin-resistant pneumococcal meningitis in an experimental rabbit model. Int. J. Antimicrob. Agents 26:258-260.
237. Suter, F., R. Maserati, G. Carnevale, P. Marone, C. Filice, and E. Concia. 1984. Management of staphylococcal endocarditis in drug addicts. Combined therapy with oral rifampicin and aminoglycosides. J. Antimicrob. Chemother. 13(Suppl. C):57-60.
238. Swanberg, L., and C. U. Tuazon. 1984. Rifampin in the treatment of serious staphylococcal infections. Am. J. Med. Sci. 287:49-54.
239. Tascini, C., G. Gemignani, F. Palumbo, A. Leonildi, A. Tedeschi, P. Lambelet, A. Lucarini, A. Piaggesi, and F. Menichetti. 2006. Clinical and microbiological efficacy of colistin therapy alone or in combination as treatment for multidrug resistant Pseudomonas aeruginosa diabetic foot infections with or without osteomyelitis. J. Chemother. 18:648-651.
240. Taylor, T. H., and M. A. Albrecht. 1995. Legionella bozemanii cavitary pneumonia poorly responsive to erythromycin: case report and review. Clin. Infect. Dis. 20:329-334.
241. Tebas, P., R. R. Martinez, F. Roman, P. Mendaza, J. C. Rodriguez Diaz, R. Daza, and J. M. de Letona. 1991. Early resistance to rifampin and ciprofloxacin in the treatment of right-sided Staphylococcus aureus endocarditis. J. Infect. Dis. 163:204-205.
242. Tripodi, M. F., E. Durante-Mangoni, R. Fortunato, R. Utili, and R. Zarrilli. 2007. Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases. Int. J. Antimicrob. Agents 30:537-540.
243. Tsaganos, T., I. Skiadas, P. Koutoukas, T. Adamis, N. Baxevanos, I. Tzepi, A. Pelekanou, E. J. Giamarellos-Bourboulis, H. Giamarellou, and K. Kanellakopoulou. 2008. Efficacy and pharmacodynamics of linezolid, alone and in combination with rifampicin, in an experimental model of methicillin-resistant Staphylococcus aureus endocarditis. J. Antimicrob. Chemother. 62:381-383.
244. Tse, K. C., S. C. Tang, T. M. Chan, and K. N. Lai. 2008. Rhodococcus lung abscess complicating kidney transplantation: successful management by combination antibiotic therapy. Transpl. Infect. Dis. 10:44-47.
245. Tsuji, B. T., and M. J. Rybak. 2006. Etest synergy testing of clinical isolates of Staphylococcus aureus demonstrating heterogeneous resistance to vancomycin. Diagn. Microbiol. Infect. Dis. 54:73-77.
246. Tuazon, C. U., M. Y. Lin, and J. N. Sheagren. 1978. In vitro activity of rifampin alone and in combination with nafcillin and vancomycin against pathogenic strains of Staphylococcus aureus. Antimicrob. Agents Chemother. 13:759-761.
247. Tunkel, A. R., B. J. Hartman, S. L. Kaplan, B. A. Kaufman, K. L. Roos, W. M. Scheld, and R. J. Whitley. 2004. Practice guidelines for the management of bacterial meningitis. Clin. Infect. Dis. 39:1267-1284.
248. Valdes, J. M., A. L. Baltch, R. P. Smith, M. C. Hammer, and W. J. Ritz. 1990. The effect of rifampicin on the in-vitro activity of cefpirome or ceftazidime in combination with aminoglycosides against Pseudomonas aeruginosa. J. Antimicrob. Chemother. 25:575-584.
249. Van der Auwera, P., and J. Klastersky. 1983. In vitro study of the combination of rifampin with oxacillin against Staphylococcus aureus. Rev. Infect. Dis. 5(Suppl. 3):S509-S514.
250. Van der Auwera, P., J. Klastersky, J. P. Thys, F. Meunier-Carpentier, and J. C. Legrand. 1985. Double-blind, placebo-controlled study of oxacillin combined with rifampin in the treatment of staphylococcal infections. Antimicrob. Agents Chemother. 28:467-472.
251. Van der Auwera, P., and P. Joly. 1987. Comparative in-vitro activities of teicoplanin, vancomycin, coumermycin and ciprofloxacin, alone and in combination with rifampicin or LM 427, against Staphylococcus aureus. J. Antimicrob. Chemother. 19:313-320.
252. van Ogtrop, M. L. 1996. Insufficient evidence of synergistic effect of levofloxacin and rifampin against Legionella pneumophila. Antimicrob. Agents Chemother. 40:524-525.
253. van Tilburg, P. M., D. Bogaert, M. Sluijter, A. R. Jansz, G. R. de Groot, and P. W. Hermans. 2001. Emergence of rifampin-resistant Streptococcus pneumoniae as a result of antimicrobial therapy for penicillin-resistant strains. Clin. Infect. Dis. 33:e93-e96.
254. Varaldo, P. E., E. Debbia, and G. C. Schito. 1985. In vitro activities of rifapentine and rifampin, alone and in combination with six other antibiotics, against methicillin-susceptible and methicillin-resistant staphylococci of different species. Antimicrob. Agents Chemother. 27:615-618.
255. Vartian, C. V., D. M. Shlaes, A. A. Padhye, and L. Ajello. 1985. Wangiella dermatitidis endocarditis in an intravenous drug user. Am. J. Med. 78:703-707.
256. Vuong, C., C. Gerke, G. A. Somerville, E. R. Fischer, and M. Otto. 2003. Quorum-sensing control of biofilm factors in Staphylococcus epidermidis. J. Infect. Dis. 188:706-718.
257. Wallace, R. J., Jr., B. A. Brown, D. E. Griffith, W. Girard, and K. Tanaka. 1995. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. J. Infect. Dis. 171:747-750.
258. Walsh, T. J., F. Auger, B. A. Tatem, S. L. Hansen, and H. C. Standiford. 1986. Novobiocin and rifampicin in combination against methicillin-resistant Staphylococcus aureus: an in-vitro comparison with vancomycin plus rifampicin. J. Antimicrob. Chemother. 17:75-82.
259. Wareham, D. W., and D. C. Bean. 2006. In-vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases. Ann. Clin. Microbiol. Antimicrob. 5:10.
260. Watanakunakorn, C. 1985. Effects of clindamycin in combination with rifampicin on clindamycin-susceptible and clindamycin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 16:335-339.
261. Watanakunakorn, C., and J. C. Guerriero. 1981. Interaction between vancomycin and rifampin against Staphylococcus aureus. Antimicrob. Agents Chemother. 19:1089-1091.
262. Watanakunakorn, C., and J. C. Tisone. 1982. Antagonism between nafcillin or oxacillin and rifampin against Staphylococcus aureus. Antimicrob. Agents Chemother. 22:920-922.
263. Wehrli, W. 1983. Rifampin: mechanisms of action and resistance. Rev. Infect. Dis. 5(Suppl. 3):S407-S411.
264. Weinstein, M. P., R. G. Deeter, K. A. Swanson, and J. S. Gross. 1991. Crossover assessment of serum bactericidal activity and pharmacokinetics of ciprofloxacin alone and in combination in healthy elderly volunteers. Antimicrob. Agents Chemother. 35:2352-2358.
265. Weinstein, M. P., C. W. Stratton, A. Ackley, H. B. Hawley, P. A. Robinson, B. D. Fisher, D. V. Alcid, D. S. Stephens, and L. B. Reller. 1985. Multicenter collaborative evaluation of a standardized serum bactericidal test as a prognostic indicator in infective endocarditis. Am. J. Med. 78:262-269.
266. Widmer, A. F., R. Frei, Z. Rajacic, and W. Zimmerli. 1990. Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. J. Infect. Dis. 162:96-102.
267. Widmer, A. F., A. Gaechter, P. E. Ochsner, and W. Zimmerli. 1992. Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations. Clin. Infect. Dis. 14:1251-1253.
268. Williams, D. L., C. Waguespack, K. Eisenach, J. T. Crawford, F. Portaels, M. Salfinger, C. M. Nolan, C. Abe, V. Sticht-Groh, and T. P. Gillis. 1994. Characterization of rifampin-resistance in pathogenic mycobacteria. Antimicrob. Agents Chemother. 38:2380-2386.
269. Yee, Y. C., B. Kisslinger, V. L. Yu, and D. J. Jin. 1996. A mechanism of rifamycin inhibition and resistance in Pseudomonas aeruginosa. J. Antimicrob. Chemother. 38:133-137.
270. Yogev, R., and J. Guzman-Cottrill. 2005. Bacterial meningitis in children: critical review of current concepts. Drugs 65:1097-1112.
271. Yost, R., T. R. Pasquale, and E. G. Sahloff. 2009. Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection. Am. J. Health Syst. Pharm. 66:715-726.
272. Yu, V. L., J. J. Zuravleff, J. E. Peacock, D. DeHertogh, and L. Tashjian. 1984. Addition of rifampin to carboxypenicillin-aminoglycoside combination for the treatment of Pseudomonas aeruginosa infection: clinical experience with four patients. Antimicrob. Agents Chemother. 26:575-577.
273. Zarrouk, V., B. Bozdogan, R. Leclercq, L. Garry, C. Feger, C. Carbon, and B. Fantin. 2001. Activities of the combination of quinupristin- dalfopristin with rifampin in vitro and in experimental endocarditis due to Staphylococcus aureus strains with various phenotypes of resistance to macrolidelincosamide-streptogramin antibiotics. Antimicrob. Agents Chemother. 45:1244-1248.
274. Zhou, S. F., C. C. Xue, X. Q. Yu, C. Li, and G. Wang. 2007. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther. Drug Monit. 29:687-710.
275. Zilly, W., D. D. Breimer, and E. Richter. 1977. Pharmacokinetic interactions with rifampicin. Clin. Pharmacokinet. 2:61-70.
276. Zimmerli, W., R. Frei, A. F. Widmer, and Z. Rajacic. 1994. Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus. J. Antimicrob. Chemother. 33:959-967.
277. Zimmerli, W., P. D. Lew, and F. A. Waldvogel. 1984. Pathogenesis of foreign body infection. Evidence for a local granulocyte defect. J. Clin. Invest. 73:1191-1200.
278. Zimmerli, W., A. Trampuz, and P. E. Ochsner. 2004. Prosthetic-joint infections. N. Engl. J. Med. 351:1645-1654.
279. Zimmerli, W., A. F. Widmer, M. Blatter, R. Frei, and P. E. Ochsner. 1998. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 279:1537-1541.
280. Zimmerman, S. W., and C. A. Johnson. 1989. Rifampin use in peritoneal dialysis. Perit. Dial. Int. 9:241-243.
281. Zinner, S. H., H. Lagast, and J. Klastersky. 1981. Antistaphylococcal activity of rifampin with other antibiotics. J. Infect. Dis. 144:365-371.
282. Zuravleff, J. J., V. L. Yu, and R. B. Yee. 1983. Ticarcillin-tobramycinrifampin: in vitro synergy of the triplet combination against Pseudomonas aeruginosa. J. Lab. Clin. Med. 101:896-902.